Format

Send to

Choose Destination
Nucleus. 2018 Jan 1;9(1):246-257. doi: 10.1080/19491034.2018.1460045.

An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.

Author information

1
a Aix Marseille Univ, INSERM, MMG - U1251 , Marseille , France.
2
b APHM, Hôpital la Timone, Service de Biologie Cellulaire , Marseille , France.
3
c APHM, Hôpital la Timone , Département de Génétique Médicale , Marseille , France.

Abstract

Hutchinson-Gilford progeria syndrome (HGPS) is a sporadic, autosomal dominant disorder characterized by premature and accelerated aging symptoms leading to death at the mean age of 14.6 years usually due to cardiovascular complications. HGPS is caused by a de novo point mutation in the LMNA gene encoding the intermediate filament proteins lamins A and C which are structural components of the nuclear lamina. This mutation leads to the production of a truncated toxic form of lamin A, issued from aberrant splicing and called progerin. Progerin accumulates in HGPS cells' nuclei and is a hallmark of the disease. Small amounts of progerin are also produced during normal aging. HGPS cells and animal preclinical models have provided insights into the molecular and cellular pathways that underlie the disease and have also highlighted possible mechanisms involved in normal aging. This review reports recent medical advances and treatment approaches for patients affected with HGPS.

KEYWORDS:

AON; FTI; HGPS; MG132; Metformin; Progerin; Rapamycin; ZOPRA

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center